

# Elisabeth Chéreau Ewald, MD., PhD.

## Titres

Ancien Chef de clinique de la Faculté de médecine Pierre et Marie Curie - Paris 6

Ancien Interne des Hôpitaux de Paris

Ancien Assistant des Hôpitaux de Paris

Ancien Praticien Hospitalier – Chirurgien des centres Institut Paoli Calmettes

## Diplomes

- Octobre 2013 **Concours de chirurgien des centres** de lutte contre le cancer : Chirurgie Gynécologique Oncologique.
- 2010-2013 **Thèse d'université.**  
Université Pierre et Marie Curie - Paris 6.  
Ecole Doctorale Physiologie et Physiopathologie (ED 394).  
Mention très honorable.
- Octobre 2010 **DESC Cancérologie** option chirurgie cancérologique
- Octobre 2009 **Thèse de Doctorat en Médecine.**  
Université René Descartes - Paris 5.  
Mention Très Honorable avec Médaille d'Argent.
- 2008-2009 **Master M2** Sciences, Technologies, Santé, Mention Biologie et Thérapies Innovantes des Grande Fonctions, spécialité Sciences Chirurgicales option **Cancérologie Chirurgicale.**  
Université Paris Sud - Paris 11, Paris.  
Laboratoire d'accueil : INSERM U747 Université René Descartes. Paris 5.
- 2003 - 2008 **Diplôme d'Etude Spécialisée (DES) Gynécologie Obstétrique.** Université René Descartes - Paris 5, Paris.
- 2006 **Diplôme Inter-universitaire d'Echographie Obstétricale et Gynécologique.** Université de Versailles Saint-Quentin-en-Yvelines. Mention bien.
- 2004 - 2005 **Master M1** Sciences de la vie et de la santé. Parcours Santé publique. Spécialité **Epidémiologie.**  
Université René Descartes - Paris 5, Paris.
- Mai 2003 **Certificat de Synthèse Clinique et Thérapeutique (CSCT).**  
Faculté de médecine Necker Enfants Malades. Université René Descartes - Paris 5, Paris.
- 2000 **Certificat de maîtrise de sciences biologiques et médicales : Ethique Déontologie et Responsabilité Médicales.**

## **Titres et Travaux**

### **Membres de sociétés savantes**

---

- Collège National des Gynécologues et Obstétriciens Français (CNGOF).
- Société Française de Chirurgie Oncologique (SFCO), membre du conseil d'administration depuis 2018.
- Société Française de Sénologie et de Pathologie Mammaire (SFSPM)

### **Responsabilités universitaires, formation médicale continue et enseignement :**

---

#### **1. Enseignement de 3<sup>ème</sup> cycle :**

- Diplôme d'Etude Spécialisé Complémentaire (DESC) de Cancérologie
- Diplôme Inter Universitaire de Pratiques Chirurgicales en Cancérologie
- Diplôme Inter Universitaire de Sénologie
- Diplôme Inter Universitaire de Colposcopie

#### **2. Enseignement aux internes de Gynécologie Obstétrique:**

#### **3. Animateur et Expert de Développement Professionnel Continu (DPC) 2008-11:**

- Cancer du col pour les médecins généralistes et les médecins gynécologues obstétriciens sous l'égide du Collège National des Gynécologues Obstétriciens Français.
- Optimiser le diagnostic, la prise en charge et le suivi des pathologies ovariennes pour les médecins généralistes et les médecins gynécologues obstétriciens.

#### **4. Membre du Conseil de Bloc de l'Hôpital Saint Joseph**

## Publications internationales:

---

1: Pomel C, Lecuru F, Leblanc E, Mathevet P, Colombo PE, Guyon F, Collinet P, Nadeau C, Huchon C, Selle F, Chereau E, Lambaudie E, Ferry P, Rafii A, Rouzier R, Ferron G; Chirurgiens du groupe GINECO. [Minimal invasive surgery for early stage cervical cancer. Recommendations from the GINECO surgeon's group]. Bull Cancer. 2019 Jul 25.

2: Pelissier A, Franke O, Darai E, Houvenaeghel G, Chereau E, Rouzier R. Value of Diaphragmatic Surgery During Interval Debulking Surgery. Anticancer Res. 2018 Jan;38(1):411-416.

3: Querleu D, Darai E, Lecuru F, Rafii A, Chereau E, Collinet P, Crochet P, Marret H, Mery E, Thomas L, Villefranque V, Floquet A, Planchamp F. [Primary management of endometrial carcinoma. Joint recommendations of the French society of gynecologic oncology (SFOG) and of the French college of obstetricians and gynecologists (CNGOF)]. Gynecol Obstet Fertil Senol. 2017 Dec;45(12):715-725.

4: Chenoz L, Phelippeau J, Barranger E, Bourdel N, Brun JL, Chereau E, Collinet P, Coutant C, Darai E, Deffieux X, Gautier T, Golfier F, Huchon C, Ouldamer L, Rouzier R, Koskas M. Evaluation and Selection of Quality Indicators for the Management of Endometrial Cancer. Int J Gynecol Cancer. 2017 Jun;27(5):979-986.

5: Zalewski K, Lindemann K, Halaska MJ, Zapardiel I, Laky R, Chereau E, Lindquist D, Polterauer S, Sukhin V, Dursun P. A Call for New Communication Channels for Gynecological Oncology Trainees: A Survey on Social Media Use and Educational Needs by the European Network of Young Gynecological Oncologists. Int J Gynecol Cancer. 2017 Mar;27(3):620-626.

6: Rouzier R, Gouy S, Selle F, Lambaudie E, Floquet A, Fourchette V, Pomel C, Colombo PE, Kalbacher E, Martin-Francoise S, Fauvet R, Follana P, Lesoin A, Lecuru F, Ghazi Y, Dupin J, Chereau E, Zohar S, Cottu P, Joly F. Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial. Eur J Cancer. 2017 Jan;70:133-142.

7: Peretti V, Chereau E, Lambaudie E, Greco F, Butarelli M, Jauffret C, Rua-Ribeiro S, Houvenaeghel G. [Single-port versus mini-laparoscopy in benign adnexal surgery: Results of a not randomized pilot study]. Gynecol Obstet Fertil. 2016 Nov;44(11):620-628.

8: Chéreau E, Uzan C, Boutmy-Deslandes E, Zohar S, Bézu C, Mazouni C, Garbay JR, Darai E, Rouzier R. Evaluation of the Effects of Pasireotide LAR Administration on Lymphocele Prevention after Axillary Node Dissection for Breast Cancer: Results of a Randomized Non-Comparative Phase 2 Study. PLoS One. 2016 Jun 9;11(6):e0156096.

- 9: Sabatier R, Sabiani L, Zemmour C, Taix S, Chereau E, Gonçalves A, Jalaguier-Coudray A, Charafe-Jauffret E, Resbeut M, Extra JM, Viens P, Tallet A. Invasive ductal breast carcinoma with predominant intraductal component: Clinicopathological features and prognosis. *Breast*. 2016 Jun;27:8-14.
- 10: Pelissier A, Bonneau C, Chéreau E, DE LA Motte Rouge T, Fourchette V, Daraï E, Rouzier R. Dynamic Analysis of CA125 Decline During Neoadjuvant Chemotherapy in Patients with Epithelial Ovarian Cancer as a Predictor for Platinum Sensitivity. *Anticancer Res*. 2016 Apr;36(4):1865-71.
- 11: Lavoué V, Fritel X, Antoine M, Beltjens F, Bendifallah S, Boisserie-Lacroix M, Boulanger L, Canlorbe G, Catteau-Jonard S, Chabbert-Buffet N, Chamming's F, Chéreau E, Chopier J, Coutant C, Demetz J, Guilhen N, Fauvet R, Kerdraon O, Laas E, Legendre G, Mathelin C, Nadeau C, Naggara IT, Ngô C, Ouldamer L, Rafii A, Roedlich MN, Seror J, Séror JY, Touboul C, Uzan C, Daraï E; French College of Gynecologists and Obstetricians (CNGOF). Clinical practice guidelines from the French College of Gynecologists and Obstetricians (CNGOF): benign breast tumors - short text. *Eur J Obstet Gynecol Reprod Biol*. 2016 May;200:16-23.
- 12: Lacorre A, Merlot B, Garabedian C, Narducci F, Chereau E, Resbeut M, Minsat M, Leblanc E, Houvenaeghel G, Lambaudie E. Early stage cervical cancer: Brachytherapy followed by type a hysterectomy versus type B radical hysterectomy alone, a retrospective evaluation. *Eur J Surg Oncol*. 2016 Mar;42(3):376-82.
- 13: Lavoué V, Fritel X, Antoine M, Beltjens F, Bendifallah S, Boisserie-Lacroix M, Boulanger L, Canlorbe G, Catteau-Jonard S, Chabbert-Buffet N, Chamming's F, Chéreau E, Chopier J, Coutant C, Demetz J, Guilhen N, Fauvet R, Kerdraon O, Laas E, Legendre G, Mathelin C, Nadeau C, Thomassin Naggara I, Ngô C, Ouldamer L, Rafii A, Roedlich MN, Seror J, Séror JY, Touboul C, Uzan C, Daraï E; Collège national des gynécologues obstétriciens français. [Benign breast tumors: Recommendations of Collège National des Gynécologues Obstétriciens Français (CNGOF)--Short text]. *J Gynecol Obstet Biol Reprod (Paris)*. 2015 Dec;44(10):1049-64.
- 14: Chamming's F, Chopier J, Mathelin C, Chéreau E. [Explorations of breast microcalcifications: Guidelines]. *J Gynecol Obstet Biol Reprod (Paris)*. 2015 Dec;44(10):960-9. doi: 10.1016/j.jgyn.2015.09.038. Epub 2015 Oct 31. Review. French.
- 15: Jauffret C, Houvenaeghel G, Classe JM, Garbay JR, Giard S, Charitansky H, Cohen M, Bélichard C, Faure C, Daraï É, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon de Lara C, Martino M, Coutant C, Dravet F, Chauvet MP, Chéreau Ewald E, Penault-Llorca F, Gonçalves A, Lambaudie É. [Lobular invasive breast cancer prognostic factors: About 940 patients]. *Gynecol Obstet Fertil*. 2015 Nov;43(11):712-7.
- 16: Houvenaeghel G, Cohen M, Jauffret-Fara C, Bannier M, Chéreau-Ewald É, Rua Ribeiro S, Lambaudie É. [Regional treatment for axillary lymph node

micrometastases of breast cancer]. *Cancer Radiother.* 2015 Jun;19(4):276-83. doi: 10.1016/j.canrad.2015.02.010. Epub 2015 May 23. Review. French.

17: Houvenaeghel G, Cohen M, Jauffret Fara C, Chéreau Ewald E, Bannier M, Rua Ribeiro S, Buttarelli M, Lambaudie E. [Sentinel lymph node-multicentric and multifocal tumors: a valid technique?]. *Gynecol Obstet Fertil.* 2015 Jun;43(6):443-8.

18: Sabatier R, Calderon B Jr, Lambaudie E, Chereau E, Provansal M, Cappiello MA, Viens P, Rousseau F. Prognostic factors for ovarian epithelial cancer in the elderly: a case-control study. *Int J Gynecol Cancer.* 2015 Jun;25(5):815-22.

19: Franké O, Narducci F, Chereau-Ewald E, Orsoni M, Jauffret C, Leblanc E, Houvenaeghel G, Lambaudie E. Role of a double docking to improve lymph node dissection: when robotically assisted laparoscopy for para-aortic lymphadenectomy is associated to a pelvic procedure. *Int J Gynecol Cancer.* 2015 Feb;25(2):331-6.

20: Ziouèche-Mottet A, Houvenaeghel G, Classe JM, Garbay JR, Giard S, Charitansky H, Cohen M, Belichard C, Faure C, Chéreau Ewald E, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon de Lara C, Tallet A, Bannier M, Minsat M, Lambaudie E, Resbeut M. Eligibility criteria for intraoperative radiotherapy for breast cancer: study employing 12,025 patients treated in two cohorts. *BMC Cancer.* 2014 Nov 24;14:868.

21: Pelissier A, Bonneau C, Chéreau E, de La Motte Rouge T, Fourchette V, Daraï E, Rouzier R. CA125 kinetic parameters predict optimal cytoreduction in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy. *Gynecol Oncol.* 2014 Dec;135(3):542-6.

22: Quaranta D, Lambaudie E, Heinnemann M, Houvenaeghel G, Chéreau E. Evaluation of single-port laparoscopy for peritoneal carcinomatosis assessment in advanced ovarian cancer. *Eur J Obstet Gynecol Reprod Biol.* 2014 Oct;181:60-5.

23: Frati A, Rouzier R, Lesieur B, Werkoff G, Antoine M, Rodenas A, Daraï E, Chereau E. Expression of somatostatin type-2 and -4 receptor and correlation with histological type in breast cancer. *Anticancer Res.* 2014 Aug;34(8):3997-4003.

24: Cohen M, Bannier M, Lambaudie E, Chéreau-Ewald E, Buttarelli M, Jauffret C, Houvenaeghel G. [Conservation of the nipple-areola complex in case of mastectomy]. *Gynecol Obstet Fertil.* 2014 Apr;42(4):246-51.

25: Laas E, Luyckx M, De Cuypere M, Selle F, Daraï E, Querleu D, Rouzier R, Chéreau E. Secondary complete cytoreduction in recurrent ovarian cancer: benefit of optimal patient selection using scoring system. *Int J Gynecol Cancer.* 2014 Feb;24(2):238-46.

26: Lambaudie E, Chereau E, Pouget N, Thomassin J, Minsat M, Charafe-Jauffret E, Jacquemier J, Houvenaeghel G. Cytokeratin 7 as a predictive factor for response to concomitant radiochemotherapy for locally advanced cervical cancer: a

preliminary study. *Anticancer Res.* 2014 Jan;34(1):177-81.

27: Houvenaeghel G, Goncalves A, Classe JM, Garbay JR, Giard S, Charytensky H, Cohen M, Belichard C, Faure C, Uzan S, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon de Lara C, Martino M, Lambaudie E, Coutant C, Dravet F, Chauvet MP, Chéreau Ewald E, Penault-Llorca F, Esterni B. Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study. *Ann Oncol.* 2014 Mar;25(3):623-8.

28: Houvenaeghel G, Cohen M, Chereau Ewald E, Bannier M, Buttarelli M, Jauffret C, Lambaudie E. [Breast cancer and axillary area: state of the art and perspectives]. *Bull Cancer.* 2013 Dec;100(12):1311-8.

29: Furet E, Chéreau E, Lambaudie E, Bannier M, Houvenaeghel G. [Feasibility, morbidity and survival of surgery combined with HIPEC in the management of recurrent ovarian cancer]. *Gynecol Obstet Fertil.* 2013 Sep;41(9):493-8.

30: Chereau E, Durand L, Frati A, Prignon A, Talbot JN, Rouzier R. Correlation of immunohistopathological expression of somatostatin receptor-2 in breast cancer and tumor detection with 68Ga-DOTATOC and 18F-FDG PET imaging in an animal model. *Anticancer Res.* 2013 Aug;33(8):3015-9.

31: Heinemann M, Hamouda S, Petrovic M, Jauffret C, Canone F, Chéreau-Ewald E, Buttarelli M, Houvenaeghel G, Lambaudie E. [Single-port surgery and adnexal procedures: which indications in oncological surgery?]. *Gynecol Obstet Fertil.* 2013 Jul-Aug;41(7-8):421-6.

32: Chéreau E, Lambaudie E, Houvenaeghel G. Morbidity of surgery after neoadjuvant chemotherapy including bevacizumab for advanced ovarian cancer. *Int J Gynecol Cancer.* 2013 Sep;23(7):1326-30.

33: Hudry D, Cannone F, Houvenaeghel G, Buttarelli M, Jauffret C, Chéreau E, Lambaudie E. Comparison of single-port laparoscopy and conventional laparoscopy for extraperitoneal para-aortic lymphadenectomy. *Surg Endosc.* 2013 Nov;27(11):4319-24.

34: Rouzier R, Pronzato P, Chéreau E, Carlson J, Hunt B, Valentine WJ. Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses. *Breast Cancer Res Treat.* 2013 Jun;139(3):621-37. doi: 10.1007/s10549-013-2559-1. Epub 2013 May 31. Review.

35: Frati A, Thomassin-Naggara I, Bazot M, Daraï E, Rouzier R, Chéreau E. Accuracy of diagnosis on CT scan of Surgicel® Fibrillar: results of a prospective blind reading study. *Eur J Obstet Gynecol Reprod Biol.* 2013 Jul;169(2):397-401.

36: Chereau E, DE LA Hosseraye C, Ballester M, Monnier L, Rouzier R, Touboul E, Daraï E. The role of completion surgery after concurrent radiochemotherapy in locally advanced stages IB2-IIB cervical cancer. *Anticancer Res.* 2013 Apr;33(4):1661-6.

37: Koskas M, Chereau E, Ballester M, Dubernard G, Lécuru F, Heitz D, Mathevet P, Marret H, Querleu D, Golfier F, Leblanc E, Luton D, Rouzier R, Daraï E. Accuracy of a nomogram for prediction of lymph-node metastasis detected with conventional histopathology and ultrastaging in endometrial cancer. *Br J Cancer*. 2013 Apr 2;108(6):1267-72.

38: Laas E, Poilroux C, Bézu C, Coutant C, Uzan S, Rouzier R, Chéreau E. Antibacterial-coated suture in reducing surgical site infection in breast surgery: a prospective study. *Int J Breast Cancer*. 2012;2012:819578.

39: Chéreau E, Lambaudie E, Ballester M, Rouzier R, Daraï E. [How i do: install extraperitoneal para-aortic single-port lymphadenectomy]. *Gynecol Obstet Fertil*. 2012 Dec;40(12):799-801.

40: Zilberman S, Ballester M, Touboul C, Chéreau E, Sèbe P, Bazot M, Daraï E. Partial colectomy is a risk factor for urologic complications of colorectal resection for endometriosis. *J Minim Invasive Gynecol*. 2013 Jan-Feb;20(1):49-55.

41: Ballester M, Naoura I, Chéreau E, Seror J, Bats AS, Bricou A, Daraï E. Sentinel node biopsy upstages patients with presumed low- and intermediate-risk endometrial cancer: results of a multicenter study. *Ann Surg Oncol*. 2013 Feb;20(2):407-12.

42: Vataire AL, Laas E, Aballéa S, Gligorov J, Rouzier R, Chéreau E. [Cost-effectiveness of a chemotherapy predictive test]. *Bull Cancer*. 2012 Oct;99(10):907-14.

43: Canlorbe G, Rouzier R, Bendifallah S, Chéreau E. [Impact of sentinel node technique on the survival in patients with vulvar cancer: analysis of the Surveillance, Epidemiology, and End Results (SEER) database]. *Gynecol Obstet Fertil*. 2012 Nov;40(11):647-51.

44: Luyckx M, Leblanc E, Filleron T, Morice P, Darai E, Classe JM, Ferron G, Stoeckle E, Pomel C, Vinet B, Chereau E, Bergzoll C, Querleu D. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study. *Int J Gynecol Cancer*. 2012 Oct;22(8):1337-43.

45: Revaux A, Rouzier R, Ballester M, Selle F, Daraï E, Chéreau E. Comparison of morbidity and survival between primary and interval cytoreductive surgery in patients after modified posterior pelvic exenteration for advanced ovarian cancer. *Int J Gynecol Cancer*. 2012 Oct;22(8):1349-54.

46: Laas E, Vataire AL, Aballea S, Valentine W, Gligorov J, Chereau E, Rouzier R. Evaluation of the costs and resource use associated with adjuvant chemotherapy for breast cancer in France. *J Med Econ*. 2012;15(6):1167-75.

47: Chéreau E, Bezu C, Gligorov J, Sakr R, Antoine M, Daraï E, Uzan S, Rouzier R. Impact of immunohistochemical analysis of sentinel lymph node biopsy on breast

cancer management. *Anticancer Res.* 2012 Aug;32(8):3403-9.

48: Chéreau E, Ballester M, Selle F, Rouzier R, Daraï E. [Clues for paraaortic lymphadenectomy in patients older than 70 years with ovarian cancer]. *Gynecol Obstet Fertil.* 2012 May;40(5):327-9.

49: Chauvin C, Chéreau E, Ballester M, Daraï E. Potential relevance of pre-operative quality of life questionnaires to identify candidates for surgical treatment of genital prolapse: a pilot study. *BMC Urol.* 2012 Mar 27;12:9.

50: Daraï E, Touboul C, Chéreau E, Bazot M, Ballester M. [Segmental resection for colorectal endometriosis: are there alternatives?]. *Gynecol Obstet Fertil.* 2012 Feb;40(2):116-20. doi: 10.1016/j.gyobfe.2011.12.002. Epub 2012 Jan 26. French.

51: Daraï E, Zilberman S, Touboul C, Chereau E, Rouzier R, Ballester M. Urological morbidity of colorectal resection for endometriosis. *Minerva Med.* 2012 Feb;103(1):63-72. Review.

52: Ramanah R, Ballester M, Chereau E, Bui C, Rouzier R, Daraï E. Anorectal symptoms before and after laparoscopic sacrocolpoperineopexy for pelvic organ prolapse. *Int Urogynecol J.* 2012 Jun;23(6):779-83.

53: Chereau E, Lavoue V, Ballester M, Coutant C, Selle F, Cortez A, Daraï E, Leveque J, Rouzier R. External validation of a laparoscopic-based score to evaluate resectability for patients with advanced ovarian cancer undergoing interval debulking surgery. *Anticancer Res.* 2011 Dec;31(12):4469-74.

54: Daraï E, Zacharopoulou C, Touboul C, Chéreau E, Ballester M. [Sentinel node procedure and endometrial cancer: senti-endo results]. *Bull Cancer.* 2012 Jan;99(1):35-41. doi: 10.1684/bdc.2011.1511. French.

55: Frati A, Chereau E, Coutant C, Bezu C, Antoine M, Chopier J, Daraï E, Uzan S, Gligorov J, Rouzier R. Comparison of two nomograms to predict pathologic complete responses to neoadjuvant chemotherapy for breast cancer: evidence that HER2-positive tumors need specific predictors. *Breast Cancer Res Treat.* 2012 Apr;132(2):601-7.

56: Chéreau E, Feron JG, Ballester M, Coutant C, Bezu C, Rouzier R, Touboul E, Daraï E. Contribution of pelvic and para-aortic lymphadenectomy with sentinel node biopsy in patients with IB2-IIB cervical cancer. *Br J Cancer.* 2012 Jan 3;106(1):39-44.

57: Ramanah R, Ballester M, Chereau E, Rouzier R, Daraï E. Effects of pelvic organ prolapse repair on urinary symptoms: a comparative study between the laparoscopic and vaginal approach. *Neurourol Urodyn.* 2012 Jan;31(1):126-31.

58: Frati A, Antoine M, Rodenas A, Gligorov J, Rouzier R, Chéreau E. [Somatostatin in breast cancer]. *Ann Biol Clin (Paris).* 2011 Jul-Aug;69(4):385-91. doi: 10.1684/abc.2011.0588. Review. French.



- 59: Ballester M, Chéreau E, Werkoff G, Zilberman S, Daraï E, Rouzier R. Laparoscopic lumbo-aortic lymph node dissection. *J Visc Surg.* 2011 Sep;148(4):e273-8.
- 60: Chéreau E, Ballester M, Daraï E. Re: "Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer". *Gynecol Oncol.* 2011 Sep;122(3):689; author reply 690.
- 61: Coussy F, Chéreau E, Daraï E, Dhombres F, Lotz JP, Rouzier R, Selle F. [Interest of CA 125 level in management of ovarian cancer]. *Gynecol Obstet Fertil.* 2011 May;39(5):296-301.
- 62: Chéreau E, Ballester M, Selle F, Rouzier R, Daraï E. Ovarian cancer in the elderly: impact of surgery on morbidity and survival. *Eur J Surg Oncol.* 2011 Jun;37(6):537-42.
- 63: Ballester M, Chéreau E, Coutant C, Daraï E, Rouzier R. Laparoscopic pelvic lymph node dissection. *J Visc Surg.* 2011 Apr;148(2):e111-6.
- 64: Chereau E, Ballester M, Gonin J, Lesieur B, Darai E. Cervical Metastasis From Colorectal Cancer. *World J Oncol.* 2011 Apr;2(2):83-84.
- 65: Chéreau E, Coutant C, Gligorov J, Lesieur B, Antoine M, Daraï E, Uzan S, Rouzier R. Discordance with local guidelines for adjuvant chemotherapy in breast cancer: reasons and effect on survival. *Clin Breast Cancer.* 2011 Mar;11(1):46-51.
- 66: Ballester M, Chereau E, Dubernard G, Coutant C, Bazot M, Daraï E. Urinary dysfunction after colorectal resection for endometriosis: results of a prospective randomized trial comparing laparoscopy to open surgery. *Am J Obstet Gynecol.* 2011 Apr;204(4):303.e1-6.
- 67: Chéreau E, Ballester M, Lesieur B, Selle F, Coutant C, Rouzier R, Daraï E. [Complications of radical surgery for advanced ovarian cancer]. *Gynecol Obstet Fertil.* 2011 Jan;39(1):21-7.
- 68: Koskas M, Chereau E, Ballester M, Selle F, Rouzier R, Daraï E. Wound complications after bevacizumab treatment in patients operated on for ovarian cancer. *Anticancer Res.* 2010 Nov;30(11):4743-7.
- 69: Bui C, Ballester M, Chéreau E, Guillo E, Daraï E. [Comparison of suture or staplin of the posterior mesh during promontofixation]. *Gynecol Obstet Fertil.* 2010 Dec;38(12):723-8. doi: 10.1016/j.gyobfe.2010.10.002. French.
- 70: Chéreau E, Rouzier R, Gouy S, Ferron G, Narducci F, Bergzoll C, Huchon C, Lécuru F, Pomel C, Daraï E, Leblanc E, Querleu D, Morice P. Morbidity of diaphragmatic surgery for advanced ovarian cancer: retrospective study of 148 cases. *Eur J Surg Oncol.* 2011 Feb;37(2):175-80.
- 71: Bui C, Ballester M, Chéreau E, Guillo E, Daraï E. [Functional results and quality of life of laparoscopic promontofixation in the cure of genital

prolapse]. *Gynecol Obstet Fertil*. 2010 Oct;38(10):563-8.

72: Ballester M, Koskas M, Coutant C, Chéreau E, Seror J, Rouzier R, Daraï E. Does the use of the 2009 FIGO classification of endometrial cancer impact on indications of the sentinel node biopsy? *BMC Cancer*. 2010 Aug 30;10:465.

73: Daraï E, Ballester M, Chereau E, Coutant C, Rouzier R, Wafo E. Laparoscopic versus laparotomic radical en bloc hysterectomy and colorectal resection for endometriosis. *Surg Endosc*. 2010 Dec;24(12):3060-7.

74: Gouy S, Chereau E, Custodio AS, Uzan C, Pautier P, Haie-Meder C, Duvillard P, Morice P. Surgical procedures and morbidities of diaphragmatic surgery in patients undergoing initial or interval debulking surgery for advanced-stage ovarian cancer. *J Am Coll Surg*. 2010 Apr;210(4):509-14.

75: Chéreau E, Uzan C, Balleyguier C, Chevalier J, de Paillerets BB, Caron O, Rimareix F, Mathieu MC, Koskas M, Bourgier C, André F, Dromain C, Delaloge S. Characteristics, treatment, and outcome of breast cancers diagnosed in BRCA1 and BRCA2 gene mutation carriers in intensive screening programs including magnetic resonance imaging. *Clin Breast Cancer*. 2010 Apr;10(2):113-8.

76: Chéreau E, Ballester M, Selle F, Cortez A, Daraï E, Rouzier R. Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. *Am J Obstet Gynecol*. 2010 Feb;202(2):178.e1-178.e10.

77: Chéreau E, Ballester M, Rouzier R, Coutant C, Daraï E. [Advanced ovarian cancer: criteria of resectability]. *Bull Cancer*. 2009 Dec;96(12):1189-97. doi: 10.1684/bdc.2009.0985. Review. French.

78: Lermite E, Marzano E, Chéreau E, Rouzier R, Pessaux P. Surgical resection of liver metastases from breast cancer. *Surg Oncol*. 2010 Dec;19(4):e79-84. doi: 10.1016/j.suronc.2009.06.005. Epub 2009 Jul 9. Review.

79: Chéreau E, Ballester M, Selle F, Cortez A, Pomel C, Daraï E, Rouzier R. Pulmonary morbidity of diaphragmatic surgery for stage III/IV ovarian cancer. *BJOG*. 2009 Jul;116(8):1062-8.

80: Chéreau E, Stefanescu D, Selle F, Rouzier R, Daraï E. Spontaneous rectovaginal fistula during bevacizumab therapy for ovarian cancer: a case report. *Am J Obstet Gynecol*. 2009 Jan;200(1):e15-6.

81: Chéreau E, Trésallet C, Cadi M, Royer B, Ewald J, Chryssostalis A, Prat F, Ménégau F. [Early diagnosis of a biliary ascariasis: report of a case]. *Gastroenterol Clin Biol*. 2007 Aug-Sep;31(8-9 Pt 1):755-7. French.

82: Chéreau E, Lejeune V, Gonzales M, Carbonne B. Voluminous fetal chylous ascites: a case of complete spontaneous prenatal regression. *Fetal Diagn Ther*. 2007;22(2):81-4.

83: Carbonne B, Chéreau E, Larsen M, Kaplan C, Brossard Y. Concomitant fetal anemia and thrombocytopenia due to anti-D and anti-HPA1a alloimmunization. *Prenat Diagn.* 2005 Dec;25(12):1172-4.

84: Raynal P, Le Meaux JP, Chéreau E. [Anthropologic evolution of women's pelvis]. *Gynecol Obstet Fertil.* 2005 Jul-Aug;33(7-8):464-8. French.